Opioid Use Disorder - Global Strategic Business Report

The global market for Opioid Use Disorder was estimated at US$5.7 Billion in 2024 and is projected to reach US$10.6 Billion by 2030, growing at a CAGR of 10.9% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Opioid Use Disorder market.

Global Opioid Use Disorder Market - Key Trends & Drivers Summarized

Why Is Opioid Use Disorder a Persistent Global Health Crisis Demanding Scalable Interventions?

Opioid Use Disorder (OUD) has escalated into a major public health emergency worldwide, particularly in North America, where synthetic opioids such as fentanyl have driven unprecedented overdose rates. The chronic, relapsing nature of OUD and its widespread socio-economic consequences have led to urgent calls for comprehensive treatment infrastructure and long-term care solutions. While awareness of the epidemic has grown significantly, so has the complexity of the crisis, which involves not only illicit drug use but also the over-prescription of opioids for pain management. With millions affected globally, healthcare systems are under pressure to adopt integrated, multi-modal approaches combining medication-assisted treatment (MAT), behavioral therapy, harm reduction, and social support. The stigma surrounding addiction, gaps in healthcare access, and the criminalization of substance use continue to hinder effective intervention strategies. However, increased public health funding, greater availability of treatment centers, and shifting perceptions of addiction as a treatable medical condition are fostering a more supportive environment for recovery. In this context, the market for OUD treatments is expanding as governments, healthcare providers, and private sector players prioritize scalable, evidence-based solutions that address both the physiological and psychological aspects of opioid dependency.

How Are Advancements in Treatment Modalities Shaping Recovery Outcomes?

The therapeutic landscape for Opioid Use Disorder is rapidly evolving, with innovation focused on improving the efficacy, safety, and accessibility of treatment options. Medication-assisted treatments (MATs) remain the cornerstone of OUD management, with methadone, buprenorphine, and naltrexone being widely used to reduce cravings, block opioid effects, and support recovery. Recent years have seen the development of extended-release formulations and implantable devices that ensure sustained medication delivery, reduce dosing frequency, and improve adherence - critical factors in long-term recovery. Novel combination therapies are also emerging to address both opioid dependence and co-occurring conditions such as depression or anxiety. Digital therapeutics and telehealth-based counseling platforms are gaining ground, especially post-COVID-19, enabling remote monitoring, therapy access, and adherence tracking. Wearable biosensors and mobile apps that provide real-time feedback and relapse alerts are being explored to support patients outside clinical environments. Additionally, research into vaccines and antagonists that block opioid receptors before the drug can exert its effects is progressing, holding promise for future prevention strategies. These advancements are not only improving patient outcomes but are also expanding treatment options in underserved and rural areas, where traditional infrastructure may be lacking.

What Systemic and Regional Factors Are Influencing Market Demand and Accessibility?

The demand for Opioid Use Disorder treatment solutions varies significantly across regions due to differences in healthcare infrastructure, policy frameworks, and socio-cultural attitudes toward addiction. In the United States and Canada, where the opioid crisis has reached epidemic levels, the focus is on expanding access to MAT, harm reduction services like naloxone distribution and safe injection sites, and integrating OUD treatment into primary care and emergency services. These countries have also seen strong government funding and regulatory support for new treatment products, including fast-tracked approvals and reimbursement programs. In contrast, developing nations often face limited access to both opioids for pain management and OUD therapies due to restrictive drug policies and underfunded healthcare systems. Stigma remains a barrier worldwide, often deterring individuals from seeking treatment or governments from investing in addiction care. However, global initiatives by organizations such as the WHO and UNODC are driving awareness and capacity-building efforts, particularly in Eastern Europe, Latin America, and parts of Asia. Meanwhile, criminal justice reforms in several countries are redirecting drug users toward treatment instead of incarceration, thereby expanding institutional demand for OUD solutions. These regional disparities and policy shifts are playing a pivotal role in shaping where and how the market for OUD treatment products and services is developing.

What Are the Primary Forces Driving Growth in the Opioid Use Disorder Market?

The growth in the Opioid Use Disorder market is driven by several factors related to rising disease prevalence, evolving treatment paradigms, technology integration, and policy shifts. A critical driver is the increasing global incidence of opioid addiction and related deaths, which is prompting urgent healthcare interventions and sustained public health funding. The widespread acceptance of medication-assisted treatment as the gold standard for OUD care is driving demand for methadone, buprenorphine, and naltrexone products, especially long-acting injectable formulations that improve adherence. Expansion of telehealth services is making treatment more accessible, particularly in rural and underserved communities, while digital platforms are facilitating patient engagement, therapy scheduling, and medication management. Regulatory support, including fast-track drug approvals, expanded prescribing authority for non-specialist providers, and insurance reimbursement reforms, is accelerating market penetration. Pharmaceutical innovation is also playing a key role, with companies investing in abuse-deterrent formulations, implants, and novel delivery methods to improve patient outcomes. Additionally, the decriminalization of substance use and the growing use of OUD treatment in correctional health systems are generating new institutional demand. Public-private partnerships and global awareness campaigns are further mobilizing resources and expanding the availability of OUD treatment across various healthcare settings. Collectively, these forces are fostering a robust, multi-faceted market environment focused on long-term recovery and systemic resilience.

Report Scope

The report analyzes the Opioid Use Disorder market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined below.

Segments: Drug (Buprenorphine Drug, Naltrexone Drug, Methadone Drug, Other Drugs); Route of Administration (Injectable Route of Administration, Oral Route of Administration, Other Route of Administrations); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels)

Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Buprenorphine Drug segment, which is expected to reach US$5.4 Billion by 2030 with a CAGR of a 12.5%. The Naltrexone Drug segment is also set to grow at 8.9% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, estimated at $1.5 Billion in 2024, and China, forecasted to grow at an impressive 9.8% CAGR to reach $1.6 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Opioid Use Disorder Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Opioid Use Disorder Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Opioid Use Disorder Market expected to evolve by 2030?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2030?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as Acadia Healthcare, Alkermes plc, Amneal Pharmaceuticals, Inc., BioDelivery Sciences International Inc., Camurus AB and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 43 Featured):

• Acadia Healthcare
• Alkermes plc
• Amneal Pharmaceuticals, Inc.
• BioDelivery Sciences International Inc.
• Camurus AB
• Collegium Pharmaceutical
• Hikma Pharmaceuticals PLC
• Indivior PLC
• Johnson & Johnson
• Lannett Company, Inc.
• Mallinckrodt Pharmaceuticals
• Novartis AG
• Omeros Corporation
• Opiant Pharmaceuticals, Inc.
• Orexo AB
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• Titan Pharmaceuticals, Inc.
• Viatris Inc. (Mylan N.V.)
• West Pharmaceutical Services, Inc.

Tariff Impact Analysis: Key Insights for 2025

Global tariff negotiations across 180+ countries are reshaping supply chains, costs, and competitiveness. This report reflects the latest developments as of April 2025 and incorporates forward-looking insights into the market outlook.

The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.

What’s Included in This Edition:

• Tariff-adjusted market forecasts by region and segment
• Analysis of cost and supply chain implications by sourcing and trade exposure
• Strategic insights into geographic shifts

Buyers receive a free July 2025 update with:

• Finalized tariff impacts and new trade agreement effects
• Updated projections reflecting global sourcing and cost shifts
• Expanded country-specific coverage across the industry